Biomarkers Guided Stopping NAs Treatment

Key Inclusion Criteria:

• 18-65 years of old, male or female

• Chronic hepatitis B patients

• Received continuous ETV, TDF or TAF therapy for at least 1 year prior to screening andat screening

• For patients with Hepatitis B e Antigen (HBeAg)-positive at the beginning of NAstherapy, documented hepatitis B virus <20 IU/mL, HBeAg seroconversion and ALTnormalization for at least 1 year prior to screening and at screening

• For patients with HBeAg-negative at the beginning of NAs therapy, documented hepatitisB virus <20 IU/mL, and ALT normalization for at least 3 year prior to screening and atscreening

• <= 9 kPa on Fibroscan assessment

• qHBsAg <200 IU/mL within 24 weeks prior to screening

• HBV RNA or HBcrAg negativity within 24 weeks prior to screening

Key Exclusion Criteria:

• Experience of IFN treatment within 1 year prior to screening

• Known cirrhosis

• History of decompensated liver disease

• History of clinical hepatic decompensation in the judgement of the investigator

• Evidence of hepatocellular carcinoma

• Serological evidence of coinfection with human immunodeficiency virus (HIV), hepatitisC virus, or hepatitis D infection

• Known hypersensitivity to TDF, its metabolites, or formulation excipients

• History of malignant disease

• Lactating females

• Females wishing to became pregnant during the duration of the study

• Subjects participating in another clinical trial